Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Novel Switch Meeting Shows Gulf Between Interests

This article was originally published in The Tan Sheet

Executive Summary

Drug manufacturers and physicians are at odds with the pharmacy industry’s expectations for the role pharmacists will have in distributing novel switches. At an FDA public hearing, CDER Director Janet Woodcock says the agency expects to “extend the concept of self-diagnosis and self-treatment to additional drugs.”

You may also be interested in...



Herbalife 'Just Getting Started' On Growth Following Flat 2019 At $4.9bn Net Sales

"We're a growth company, well-positioned in a global trend of nutrition that the world hasn't seen before," says co-president John Agwunobi. But the direct seller's record volume increase in 2019 didn’t translate to revenue growth as China, Mexico and Central and South America pulled down results.

Coronavirus Drives TCM Sales In China, Clouds Global Consumer Health Outlook

Consumer health product firms say the coronavirus will have an impact on their results, but it’s too early to estimate the costs. US FDA also hedges its predictions, saying the outbreak could lead to interruptions in country’s drug and medical device supplies. China's health commission has issued six guidelines for diagnosis and treatment, but no conventional antiviral treatment is approved and it's emphasizing traditional Chinese medicines.

Pataday Switch Appoval Dilates Eye Drop Category As Alcon's OTC Sales Driver

With Pataday Once Daily Relief (0.2% olopatadine) and Twice Daily (0.1%), Alcon adds allergy treatment to its lineup of OTC drops indicated for dry eye and redness. “Obviously, eye allergy will become a much bigger part of the portfolio for us,” says US vision care GM Sean Clark.

Topics

UsernamePublicRestriction

Register

PS105643

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel